Aim： To compare the results of bladder tumor associated antigen （BTA TRAK）, nuclear matrix protein 22 （NMP 22） and voided urine cytology （VUC） in detecting bladder cancer. Methods： A total of 135 elderly male ...Aim： To compare the results of bladder tumor associated antigen （BTA TRAK）, nuclear matrix protein 22 （NMP 22） and voided urine cytology （VUC） in detecting bladder cancer. Methods： A total of 135 elderly male and 50 healthy volunteers enrolled in this study were classified into three groups： （i） 93 patients with bladder cancer; （ii） 42 patients with urinary benign conditions; and （iii） 50 healthy volunteers. BTA TRAK and NMP 22 kits were used to detect bladder cancer. Voided urine cytology was used to compare the sensitivity and specificity of the screening tests. Results： The sensitivity and specificity of cytology, BTA TRAK and NMP 22 were 24% and 97%, 51% and 73%, 78% and 73%, respectively. The level of NMP 22 increased with tumor grading. The BTA TRAK kit has the lowest sensitivity among the screening tests. The NMP 22 with the best sensitivity can be an adjunct to cytology for evaluating bladder cancer. Conclusion： The NMP 22 test has a better correlation with the grading of the bladder cancer than BTA TRAK. As cytology units are typically not available in hospitals or in outpatient clinics, NMP 22 might be a promising tool for screening bladder cancer.展开更多
为评价尿膀胱癌抗原(urinary bladder cancer antigen,UBC)在膀胱移行细胞癌(BTCC)中的诊断价值,采用ELISA法对53例BTCC患者、25例泌尿系统良性疾病患者和13例健康志愿者进行UBC检测,并同时行尿细胞学检查。结果显示:(1)BTCC患者UBC平...为评价尿膀胱癌抗原(urinary bladder cancer antigen,UBC)在膀胱移行细胞癌(BTCC)中的诊断价值,采用ELISA法对53例BTCC患者、25例泌尿系统良性疾病患者和13例健康志愿者进行UBC检测,并同时行尿细胞学检查。结果显示:(1)BTCC患者UBC平均含量为26.26±28.49μg/L,与泌尿系统良性疾病患者和健康志愿者相比(9.41±9.63μg/L、1.73±0.79μg/L),均有显著性差异(P均<0.01)。(2)以7.5μg/L为最适临界值时,UBC诊断BTCC的敏感性和特异性分别为86.8%、76.3%,与尿细胞学检查(32.1%、97.4%)相比,均有显著性差异(P均<0.01)。结论:UBC具有简便、敏感和无创的特点,可作为辅助诊断BTCC的尿肿瘤标志物。展开更多
目的:评价尿膀胱癌抗原(urinary bladder cancer antigen,UBC)、CYFRA21-1和透明质酸(hyaluronic acid,HA)在膀胱癌诊断中的应用价值。方法:采用ELISA法检测53例膀胱癌患者、25例泌尿系统良性疾病患者和13名健康志愿者的尿UBC,并采用RI...目的:评价尿膀胱癌抗原(urinary bladder cancer antigen,UBC)、CYFRA21-1和透明质酸(hyaluronic acid,HA)在膀胱癌诊断中的应用价值。方法:采用ELISA法检测53例膀胱癌患者、25例泌尿系统良性疾病患者和13名健康志愿者的尿UBC,并采用RIA法检测其CYFRA21-1和HA,同时行尿细胞学检查。结果:①通过ROC曲线确定UBC、CYFRA21-1和HA的最适临界值分别为7.5μg/L、2.85ng/mL和154.47ng/mL,3种尿肿瘤标志诊断膀胱癌的灵敏度分别为86.8%、86.8%、71.7%,与尿细胞学检查(32.1%)相比差异均有统计学意义(P<0.01);4种方法的特异度分别为76.3%、78.9%、84.2%、97.4%;阳性预期值分别为83.6%、85.2%、86.4%、94.4%;阴性预期值分别为80.6%、81.1%、68.1%、50.7%。②3种尿肿瘤标志联合检测诊断灵敏度可提高至96.2%。结论:尿UBC、CYFRA21-1和HA检测技术简便,具较高的灵敏度和特异度,其联合检测更有助于诊断膀胱癌。展开更多
文摘Aim： To compare the results of bladder tumor associated antigen （BTA TRAK）, nuclear matrix protein 22 （NMP 22） and voided urine cytology （VUC） in detecting bladder cancer. Methods： A total of 135 elderly male and 50 healthy volunteers enrolled in this study were classified into three groups： （i） 93 patients with bladder cancer; （ii） 42 patients with urinary benign conditions; and （iii） 50 healthy volunteers. BTA TRAK and NMP 22 kits were used to detect bladder cancer. Voided urine cytology was used to compare the sensitivity and specificity of the screening tests. Results： The sensitivity and specificity of cytology, BTA TRAK and NMP 22 were 24% and 97%, 51% and 73%, 78% and 73%, respectively. The level of NMP 22 increased with tumor grading. The BTA TRAK kit has the lowest sensitivity among the screening tests. The NMP 22 with the best sensitivity can be an adjunct to cytology for evaluating bladder cancer. Conclusion： The NMP 22 test has a better correlation with the grading of the bladder cancer than BTA TRAK. As cytology units are typically not available in hospitals or in outpatient clinics, NMP 22 might be a promising tool for screening bladder cancer.
文摘为评价尿膀胱癌抗原(urinary bladder cancer antigen,UBC)在膀胱移行细胞癌(BTCC)中的诊断价值,采用ELISA法对53例BTCC患者、25例泌尿系统良性疾病患者和13例健康志愿者进行UBC检测,并同时行尿细胞学检查。结果显示:(1)BTCC患者UBC平均含量为26.26±28.49μg/L,与泌尿系统良性疾病患者和健康志愿者相比(9.41±9.63μg/L、1.73±0.79μg/L),均有显著性差异(P均<0.01)。(2)以7.5μg/L为最适临界值时,UBC诊断BTCC的敏感性和特异性分别为86.8%、76.3%,与尿细胞学检查(32.1%、97.4%)相比,均有显著性差异(P均<0.01)。结论:UBC具有简便、敏感和无创的特点,可作为辅助诊断BTCC的尿肿瘤标志物。
文摘目的:评价尿膀胱癌抗原(urinary bladder cancer antigen,UBC)、CYFRA21-1和透明质酸(hyaluronic acid,HA)在膀胱癌诊断中的应用价值。方法:采用ELISA法检测53例膀胱癌患者、25例泌尿系统良性疾病患者和13名健康志愿者的尿UBC,并采用RIA法检测其CYFRA21-1和HA,同时行尿细胞学检查。结果:①通过ROC曲线确定UBC、CYFRA21-1和HA的最适临界值分别为7.5μg/L、2.85ng/mL和154.47ng/mL,3种尿肿瘤标志诊断膀胱癌的灵敏度分别为86.8%、86.8%、71.7%,与尿细胞学检查(32.1%)相比差异均有统计学意义(P<0.01);4种方法的特异度分别为76.3%、78.9%、84.2%、97.4%;阳性预期值分别为83.6%、85.2%、86.4%、94.4%;阴性预期值分别为80.6%、81.1%、68.1%、50.7%。②3种尿肿瘤标志联合检测诊断灵敏度可提高至96.2%。结论:尿UBC、CYFRA21-1和HA检测技术简便,具较高的灵敏度和特异度,其联合检测更有助于诊断膀胱癌。
